Thus, therapeutic strategies against dyslipidemia (e.g., statins) may be important in improving clinical outcomes in this patient population [6]; however, the effects of uric acid-lowering medications on lipid profiles remain unclear, particularly in the case of newer XO inhibitors. Here, XDH is linked to metabolic syndrome.